METHODS OF TREATMENT WITH MYOSIN MODULATOR

Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments. Due to observations unfolding in c...

Full description

Saved in:
Bibliographic Details
Main Authors LI, WANYING, MCDOWELL, ROBERT, FERNANDES, SARAH, NISSEN, STEVE, KANE, BRIAN EDMUND, EDELBERG, JAY M, HENZE, MARCUS PATRICK, SEHNERT, AMY, LAMBING, JOSEPH, SEHL, LOUIS CHARLES, SEMIGRAN, MARC J, ZHANG, DAVID, MA, GRACE YANFEI, LAMPL, KATHY L, FANG, LIANG, CARLSON, TIMOTHY, DEL RIO, CARLOS L, DESAI, MILIND Y, MEALIFFE, MATTHEW EDWARDS, AUBELE, DANIELLE L
Format Patent
LanguageEnglish
French
Published 14.05.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments. Due to observations unfolding in clinical trials with mavacamten and with mavacamten and other myosin inhibitors in the pre-clinical setting, new insights into how myosin inhibitors can be used beneficially to impact the disease state of HCM and other diseases are provided herein. L'invention concerne des méthodes de traitement consistant à administrer une quantité thérapeutiquement efficace d'un modulateur de myosine ou d'un sel pharmaceutiquement acceptable de celui-ci à un patient qui en a besoin et des méthodes de diagnostic utiles en relation avec ces traitements. Du fait d'observations se révélant lors d'essais cliniques avec du mavacamten et avec du mavacamten et d'autres inhibiteurs de myosine dans le cadre préclinique, l'invention concerne également de nouveaux aperçus de la manière avec laquelle des inhibiteurs de myosine peuvent être avantageusement utilisés pour avoir un impact sur l'état pathologique de CMH et d'autres maladies.
AbstractList Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable salt thereof to a subject in need thereof and diagnostic methods useful in connection with those treatments. Due to observations unfolding in clinical trials with mavacamten and with mavacamten and other myosin inhibitors in the pre-clinical setting, new insights into how myosin inhibitors can be used beneficially to impact the disease state of HCM and other diseases are provided herein. L'invention concerne des méthodes de traitement consistant à administrer une quantité thérapeutiquement efficace d'un modulateur de myosine ou d'un sel pharmaceutiquement acceptable de celui-ci à un patient qui en a besoin et des méthodes de diagnostic utiles en relation avec ces traitements. Du fait d'observations se révélant lors d'essais cliniques avec du mavacamten et avec du mavacamten et d'autres inhibiteurs de myosine dans le cadre préclinique, l'invention concerne également de nouveaux aperçus de la manière avec laquelle des inhibiteurs de myosine peuvent être avantageusement utilisés pour avoir un impact sur l'état pathologique de CMH et d'autres maladies.
Author LI, WANYING
HENZE, MARCUS PATRICK
MCDOWELL, ROBERT
AUBELE, DANIELLE L
NISSEN, STEVE
LAMBING, JOSEPH
CARLSON, TIMOTHY
EDELBERG, JAY M
SEMIGRAN, MARC J
LAMPL, KATHY L
SEHNERT, AMY
SEHL, LOUIS CHARLES
DEL RIO, CARLOS L
MA, GRACE YANFEI
KANE, BRIAN EDMUND
FANG, LIANG
DESAI, MILIND Y
FERNANDES, SARAH
ZHANG, DAVID
MEALIFFE, MATTHEW EDWARDS
Author_xml – fullname: LI, WANYING
– fullname: MCDOWELL, ROBERT
– fullname: FERNANDES, SARAH
– fullname: NISSEN, STEVE
– fullname: KANE, BRIAN EDMUND
– fullname: EDELBERG, JAY M
– fullname: HENZE, MARCUS PATRICK
– fullname: SEHNERT, AMY
– fullname: LAMBING, JOSEPH
– fullname: SEHL, LOUIS CHARLES
– fullname: SEMIGRAN, MARC J
– fullname: ZHANG, DAVID
– fullname: MA, GRACE YANFEI
– fullname: LAMPL, KATHY L
– fullname: FANG, LIANG
– fullname: CARLSON, TIMOTHY
– fullname: DEL RIO, CARLOS L
– fullname: DESAI, MILIND Y
– fullname: MEALIFFE, MATTHEW EDWARDS
– fullname: AUBELE, DANIELLE L
BookMark eNrjYmDJy89L5WTQ8nUN8fB3CVbwd1MICXJ1DPF19QtRCPcM8VDwjfQP9vRT8PV3CfVxDPEP4mFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8c6Oxoam5mZGlo6GxkQoAQAIoiYm
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate METHODES DE TRAITEMENT COMPRENANT UN MODULATEUR DE MYOSINE
ExternalDocumentID CA3157629A1
GroupedDBID EVB
ID FETCH-epo_espacenet_CA3157629A13
IEDL.DBID EVB
IngestDate Fri Aug 02 08:57:02 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CA3157629A13
Notes Application Number: CA20203157629
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210514&DB=EPODOC&CC=CA&NR=3157629A1
ParticipantIDs epo_espacenet_CA3157629A1
PublicationCentury 2000
PublicationDate 20210514
PublicationDateYYYYMMDD 2021-05-14
PublicationDate_xml – month: 05
  year: 2021
  text: 20210514
  day: 14
PublicationDecade 2020
PublicationYear 2021
RelatedCompanies MYOKARDIA, INC
RelatedCompanies_xml – name: MYOKARDIA, INC
Score 3.328901
Snippet Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of a myosin modulator or a pharmaceutically acceptable...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title METHODS OF TREATMENT WITH MYOSIN MODULATOR
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210514&DB=EPODOC&locale=&CC=CA&NR=3157629A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fT8IwEL4QNOqbokb8lT6YPZgsMtox-7CY0W0ZxlECRfGJ0MESXoDIjP--1wXQF31r2uTaXvL17uv1rgB3TZq3PI9y29Afmzkst3meU1ubqpANJ-eammzktNtKhux55I4qMN_mwpR1Qr_K4oiIqAzxXpTn9ernEiss31auH_Qcu5ZPsfJDa8OOkb-gA2CFbT_qyVAKSwhfBFa371MHHesmD5Ao7aEX7RkwRK9tk5Sy-m1R4mPY76GwRXECldmiBodi-_FaDQ7STbwbmxvorU_hPo1UIsMBkTFR_ShQpgo_eeuohKTvctDpklSGw5dAyf4ZkDhSIrFx0vFug2MR7JZHz6GKvH92ASTz9KPLpy5HlLBGNpkwnfEGz7SnpyzjtA71P8Vc_jN2BUdGUyYE7rBrqBYfn7MbtKyFvi118g3qPngq
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT8IwEL8QNOKbokbwqw9mDyaLjBZmHxYz9pGhbCVQFJ8IHSzhBYnM-O97XQB90bemTa7tJb_e_Xq9K8Btk2Zt26bc1PTHZBbLTJ5l1FS6KmTDyriiOhs5TtrRiD2NW-MSLLa5MEWd0K-iOCIiKkW858V5vfq5xPKLt5Xre7XArvfHUDq-sWHHyF_QATD8jhP0hS88w_MczzWSgUMtdKyb3EWitIcetq3BELx0dFLK6rdFCY9gv4_ClvkxlObLKlS87cdrVTiIN_FubG6gtz6BuziQkfCHRIREDgJX6ir85LUrIxK_iWE3IbHwRz1XisEpkDCQXmTipJPdBieeu1sePYMy8v75OZDUVg8tPmtxRAlrpNMpUylv8FTZasZSTmtQ-1NM_Z-xG6hEMu5Net3k-QIOtdZ0ONxil1DOPz7nV2hlc3Vd6Ocbt957HQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=METHODS+OF+TREATMENT+WITH+MYOSIN+MODULATOR&rft.inventor=LI%2C+WANYING&rft.inventor=MCDOWELL%2C+ROBERT&rft.inventor=FERNANDES%2C+SARAH&rft.inventor=NISSEN%2C+STEVE&rft.inventor=KANE%2C+BRIAN+EDMUND&rft.inventor=EDELBERG%2C+JAY+M&rft.inventor=HENZE%2C+MARCUS+PATRICK&rft.inventor=SEHNERT%2C+AMY&rft.inventor=LAMBING%2C+JOSEPH&rft.inventor=SEHL%2C+LOUIS+CHARLES&rft.inventor=SEMIGRAN%2C+MARC+J&rft.inventor=ZHANG%2C+DAVID&rft.inventor=MA%2C+GRACE+YANFEI&rft.inventor=LAMPL%2C+KATHY+L&rft.inventor=FANG%2C+LIANG&rft.inventor=CARLSON%2C+TIMOTHY&rft.inventor=DEL+RIO%2C+CARLOS+L&rft.inventor=DESAI%2C+MILIND+Y&rft.inventor=MEALIFFE%2C+MATTHEW+EDWARDS&rft.inventor=AUBELE%2C+DANIELLE+L&rft.date=2021-05-14&rft.externalDBID=A1&rft.externalDocID=CA3157629A1